Silk Road Medical Appoints World Class Stroke Prevention Champion to Serve as Vice President, Medical Affairs and Professional Education
Tammy Leitsinger to spearhead global physician education and peer-to-peer training for rapidly growing Trans Carotid Artery Revascularization (TCAR) procedure
SUNNYVALE, Calif., Oct. 11, 2017 /PRNewswire/ -- Silk Road Medical, Inc., a company dedicated to preventing the devastating burden of stroke through surgical innovation, announces the appointment of Tammy Leitsinger to the position of Vice President, Medial Affairs and Professional Education. In this new role, Tammy will further develop and refine global, peer-to-peer TCAR training pathways and innovative educational programs.
Prior to joining Silk Road Medical, Tammy was Vice President, Global Clinical Solutions, Cordis Corporation, Cardinal Health and has over 25 years of clinical education and global market development in the endovascular, cardiovascular, neurovascular and endoscopy arenas and has a profound understanding of carotid revascularization via transfemoral carotid artery stenting (TF-CAS). "Tammy has an absolutely stellar reputation with both industry and physician key opinion leaders in our vascular domain. Tammy also brings in-depth expertise in global healthcare compliance policy and government regulations which will serve Silk Road Medical well as we commercialize TCAR at an accelerated pace," said Sumaira Macdonald MD PhD, Chief Medical Officer.
"The quest for a minimally invasive, endovascular solution for patients with carotid artery disease has been extensive and challenging due to the high risk of devastating complications," said Leitsinger. "The TCAR procedure addresses these legacy risks and is clearly the pathway forward. I look forward to working with the team to help drive TCAR to standard of care for carotid disease patients at risk for traditional surgery."
About TCAR with the ENROUTE Transcarotid Neuroprotection and Stent System:
TCAR is a clinically proven procedure combining surgical principles of neuroprotection with minimally invasive endovascular techniques to treat blockages in the carotid artery at risk of causing a stroke. The ENROUTE Transcarotid Stent is intended to be used in conjunction with the ENROUTE Transcarotid Neuroprotection System (NPS) during the TCAR procedure. The ENROUTE Transcarotid NPS is a first in class device used to directly access the common carotid artery and initiate high rate temporary blood flow reversal to protect the brain from stroke while delivering and implanting the ENROUTE Transcarotid Stent.
About Silk Road Medical, Inc.
Silk Road Medical, Inc. is a private company located in Sunnyvale, CA, that develops and manufactures less-invasive medical devices intended to improve the treatment of carotid artery disease through proprietary transcarotid therapies. Detailed information can be found at www.silkroadmed.com.
ENROUTE and the Silk Road logo are registered trademarks of Silk Road Medical, Inc.
SOURCE Silk Road Medical, Inc.
Share this article